12 completed, 1 not yet recruiting, 1 withdrawn. 14 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 12, Not yet recruiting 1, Withdrawn 1 |
Follow Chronic Plaque Psoriasis: new trials by email Literature Review of Chronic Plaque Psoriasis trials Research Report on Chronic Plaque Psoriasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparative Study on Unani Formulation Vs Active Control in Plaque Psoriasis Marham Asfedaj, Mundij wa Mushil Sawda (Unani Oral decoction), Coal tar 1% & Salicylic acid 3 % solution - Chronic Plaque Psoriasis, Plaque Psoriasis | Phase 2 | Not yet recruiting | National Institute of Unani Medicine, Bengaluru | 54 | 2027-04-01 | 2026-09-25 |
| A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis Bimekizumab - Chronic Plaque Psoriasis | Phase 2 | Completed | UCB Biopharma SRL | 43 | 2017-07-03 | 2022-07-22 |
| A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis Bimekizumab, Placebo - Chronic Plaque Psoriasis | Phase 2 | Completed | UCB Biopharma SRL | 49 | 2016-12-27 | 2026-03-24 |
| A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis Bimekizumab, Placebo - Chronic Plaque Psoriasis | Phase 2 | Completed | UCB Biopharma SRL | 217 | 2016-12-14 | 2022-10-18 |
| Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis PF-06700841, Placebo - Chronic Plaque Psoriasis | Phase 2 | Completed | Pfizer | 212 | 2016-12-01 | 2019-03-29 |
| A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis Belumosudil, Placebo - Chronic Plaque Psoriasis | Phase 2 | Completed | Kadmon Corporation, LLC | 110 | 2016-09-14 | 2022-03-16 |
| Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis Bimekizumab, Placebo - Chronic Plaque Psoriasis | Phase 2 | Completed | UCB Biopharma S.P.R.L. | 250 | 2016-08-01 | 2022-07-21 |
| Skin Transcriptional Profiles In Psoriatic Patients Under Adalimumab Biotherapy Adalimumab Every Week - Chronic Plaque Psoriasis | Phase 2 | Completed | Poitiers University Hospital | 18 | 2013-01-01 | 2026-06-24 |
| Apremilast for Chronic Plaque Psoriasis (CPP) Patients Who Have Failed One Course of Biologic Therapy apremilast - Chronic Plaque Psoriasis | Phase 2 | Withdrawn | Duke University | 2010-09-01 | 2014-07-15 | |
| Multiple-loading Dose Regimen Study in Patients With Chronic Plaque-type Psoriasis AIN457, Placebo - Chronic Plaque Psoriasis | Phase 2 | Completed | Novartis Pharmaceuticals | 130 | 2008-12-01 | 2015-02-10 |
| Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis AIN457, Placebo - Chronic Plaque Psoriasis | Phase 2 | Completed | Novartis Pharmaceuticals | 80 | 2008-09-10 | 2018-03-12 |
| Paired-Comparison Study Evaluating the Efficacy and Safety of E6201 Versus Vehicle for the Treatment of Plaque-Type Psoriasis E6201 0.005%, E6201 0.01%, E6201 0.03% - Chronic Plaque Psoriasis | Phase 2 | Completed | Eisai Inc. | 100 | 2007-09-01 | 2017-02-06 |
| A Study of Calcitriol BID Topical Treatment in Adolescents With Plaque Psoriasis Calcitriol 3mcg/g - Chronic Plaque Psoriasis | Phase 2 | Completed | Galderma R&D | 25 | 2006-08-01 | 2021-02-18 |
| Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/Photochemotherapy Certolizumab Pegol, Placebo - Chronic Plaque Psoriasis | Phase 2 | Completed | UCB Pharma | 176 | 2005-10-01 | 2019-05-03 |
Psoriasis (7) · Skin Diseases (3) · Plaque, Amyloid (2) · Autoimmune Diseases (1) · Dermatitis (1)
Skin and Connective Tissue Diseases (9) · Skin Diseases, Papulosquamous (7) · Skin Diseases (6) · Pathological Conditions, Anatomical (2) · Pathological Conditions, Signs and Symptoms (2) · Immune System Diseases (1)
bimekizumab (4) · secukinumab (2) · Calcitriol (1) · Certolizumab Pegol (1) · Coal Tar (1) · KD025 (1) · PF-06700841 (1) · Salicylic Acid (1) · Solutions (1) · apremilast (1) · belumosudil (1)
UCB Biopharma SRL (3) · Novartis Pharmaceuticals (2) · Duke University (1) · Eisai Inc. (1) · Galderma R&D (1) · Kadmon Corporation, LLC (1) · National Institute of Unani Medicine, Bengaluru (1) · Pfizer (1) · Poitiers University Hospital (1) · UCB Biopharma S.P.R.L. (1) · UCB Pharma (1)
United States (10) · Canada (6) · Poland (3) · Australia (2) · Czechia (2) · France (2) · Hungary (2) · Japan (2) · Moldova (2) · Germany (1) · India (1)
John C Murray, MD (1) · Michael Graeber, MD (1)
PMID 35544084, PMID 22413944, PMID 29171393, PMID 30113844, PMID 32311398, PMID 32473974, PMID 34687214, PMID 36045513, PMID 37315881, PMID 41580158
2016 (5), 2005 (1)